摘要
目的:了解洛铂联合多西他赛在复发性卵巢癌患者中的疗效和安全性。方法:在2011年1月至2013年1月之间,收集31例在湖南省肿瘤医院经组织病理学或细胞学诊断为复发性卵巢癌的患者。31例患者在接受洛铂联合化学治疗(化疗)前均接受了以顺铂或卡铂为基础的联合化疗方案。治疗中多西他赛80 mg/m2,第1天静脉化疗,洛铂为30 mg/m2,第2天静脉化疗,21 d为1个周期,最多进行6个周期的治疗,31例患者共完成153个周期的化疗。分析治疗后的总有效率、疾病控制率、无进展生存期和毒副作用。结果:31例患者中3例达到了完全缓解,11例部分缓解,2例疾病稳定,15例疾病进展,总有效率为45.16%(95%CI:26.61%~63.72%),DCR为51.63%(95%CI:32.98%~70.25%),中位无进展生存期为7个月(95%CI:4.27~9.73个月)。毒副作用中:1例3级白细胞减少,21例1~2级白细胞减少,18例1~2级中性粒细胞减少,17例1~2级贫血,2例1级血小板减少;消化道反应恶心、呕吐的发生较为温和且可以控制。未见严重的肝肾功能损伤。结论:洛铂联合多西他赛对复发性和难治性卵巢癌具有较好的抗肿瘤效应,疗效明显优于其他二线化疗方案,且具有较低的毒副作用。
Objective: To evaluate the efficacy and safety of lobaplatin combined with docetaxel in the treatment of the recurrent ovarian carcinoma. Methods: We collected 31 patients who diagnosed as recurrent ovarian carcinoma according to the histopathology or cytology from Tumor Hospital of Hunan Province from January 2011 to January 2013. The patients received cisplatin-based chemotherapy or carboplatin-based chemotherapy before the combined chemotherapy of docetaxel and lobaplatin. For patients with the recurrence, they received a treatment at a dose of 80 mg/m2 for docetaxel on day 1 and a dose of 30 mg/m2 for lobaplatin on day 2, which lasted for 21 days as a treatment cycle. hTe patients received 6-cycletreatment at most. Results: A total of 153 cycles of chemotherapy were given to 31 patients, with a median of 4 (2–6) cycles. Three patients showed complete response, 11 partial response, 2 stable disease, and 15 progressive disease. hTe objective response rate (ORR) was 45.16% (95% CI, 26.61%–63.72%), and the disease control rate (DCR) was 51.63% (95% CI, 32.98%–70.25%). The median progression-free survival was 7 months (95% CI, 4.27–9.73 months). For the toxic and side effects among the 31 patients, the numbers of the grade 3, grade 2, and grade 1 leukopenia were 1, 8, and 13, respectively. Meanwhile, 18 were grade 1–2 neutropenia, 17 grade 1–2 anemia, and 2 grade 1 thrombocytopenia. At the same time, alimentary canal reaction followed by nausea and vomiting was relatively modest and could be controlled. hTe serious damage of hepatic-renal function was not found. Conclusion: The chemotherapy of lobaplatin combined with docetaxel is effective on recurrent and refractory ovarian cancer with low side effects, which has advantages over the second-line chemotherapy protocols.
出处
《中南大学学报（医学版）》
CAS
CSCD
北大核心
2014年第11期1131-1136,共6页
Journal of Central South University ：Medical Science
关键词
复发性卵巢癌
洛铂
多西他赛
relapsed ovarian cancer
lobaplatin
docetaxel
